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ABSTRACT
Objective: There were main two objectives, first was the identification of best biomarkers for early screening of kidney diseases whether plasma urea 
and creatinine or novel urinary low molecular weight protein biomarkers Interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), and cystatin-C. 
Second was the therapeutic efficacy of methanol fraction of Terminalia arjuna (MFTA) on urinary novel biomarkers.
Methods: A total of 35 adult male rats were divided into three Groups (n=5), Group 1 was fed normal food, Group 2, normal food with administration 
of acetaminophen (APAP) for 5 days, 10 days, and 15 days, and Group 3, normal food with administration of APAP and coadministration of MFTA for 
5 days, 10 days, and 15 days. All rats were sacrificed at 15th day of the experiment.
Results: Results showed 5 days, 10 days, and 15 days administrations of APAP increased novel urinary biomarkers as IL-18, KIM-1 near two-folds 
and cystatin-C near six-folds increased than old biomarkers plasma urea and plasma creatinine. Administration of APAP with coadministration of 
MFTA represented the protective effect by decreasing old and new novel biomarkers with superoxide dismutase and catalase but malondialdehyde 
level increased. Sodium dodecyle sulphate-polyacrylamide gel electrophoresis showed new low molecular weight urinary protein bands in APAP 
administration rats, the protective effect of MFTA presents no band at this molecular level as normal rats.
Conclusion: MFTA is the most potent nephroprotective agent, and urinary low molecular proteins are the best thing diagnostic tools for early 
detection of kidney disease over common plasma urea and creatinine.
Keywords: Kidney Disease, Acetaminophen, Nephrotoxicity, Biomarkers, Terminalia arjuna, Nephroprotective, Rat.
INTRODUCTION
Chronic kidney disease (CKD) is an irreversible progressive disorder 
of structural and functional changes in kidney parenchyma into five 
stages on the presence of decreased kidney function and measured 
by the concentration of serum creatinine and estimated glomerular 
filtration rate [1]. However, the use of serum creatinine to detect 
kidney disease which is poor in assay specificity and sensitivity to 
delayed diagnosis and treatment timing. Kidney disease becomes more 
fatal and severe with comorbid disorders, reactive oxygen species, 
diabetes mellitus, hypertension, etc. [2]. From the earlier background 
of our research, different anti-uremic and renoprotective plant extract 
such as phytocompounds from Terminalia arjuna (TA) [3], Asparagus 
racemosus [4], and Withania somnifera [5] which efficiently played 
as a remedy on experimentally induced uremic and oxidative stress 
rats. Alternative therapy such as alpha lipoic acid [6] and probiotic [7] 
shown brilliance nephroprotective action against the administration 
of acetaminophen (APAP)-induced renal failure male rats in our 
laboratory [8]. In early research anti-uremic and anti-oxidative activity 
of TA (Family - Combretaceae) is already established [9]. Therefore, the 
aim of the study was to evaluate early urinary biomarkers such as kidney 
injury molecule-1 (KIM-1), Interleukin-18 (IL-18), and cystatin-C at an 
early stage of kidney diseases. KIM-1 appears in urine by specific mild 
renal tubular disorder [10], IL-18 for proximal tubular necrosis [11], 
and cystatin-C for kidney tissue macrophages cell in collecting duct [12] 
after duration dependent induction of kidney disease by peritoneal 
administration of acetaminophen in rats and also evaluate the urinary 
protein band by protein gel electrophoresis that was best result of 
protein marker would be sequence and identified in future.
METHODS
Reagents
Major biochemical parameters such as urea and creatinine were 
measured by diagnostic kits supplied by Spinreact, S.A.U. - Ctra, Santa 
Coloma, and Spain. We used Enzyme-linked immunosorbent assay 
(ELISA) kit like IL-18; KIM-1 supplied by Thermofisher Scientific, 
in vitro gen Bioservices India Pvt. Ltd., Bengaluru, India. Other chemicals 
were purchased from SRL, India and MERCK, India, SD FINE-CHEM 
Limited, India, HiMedia Laboratories Pvt. Ltd. Mumbai, India, and Crest 
Biosystems Goa, India, and Gland Pharma Limited, India.
Instruments
Biochemical parameters such as urea and creatinine were monitored by 
semi autoanalyzer (Diasil-100). Superoxide dismutase (SOD), catalase, 
and malondialdehyde (MDA) were monitored by Ultraviolet-visible 
spectrophotometer (UV-VIS spectrophotometer) (Systronics, India). 
IL-18, KIM-1, and Cystatin-C were measured by ELISA Plate Reader 
(Thermofisher Scientific, India). Plant material fraction extract was 
done using an electrical blender (Japan, India), Microcentrifuges (Remi, 
India), Digital weight balance (Accuracy-0.1 mg Adhair Dutta and Sons), 
and pH meter (Mettler, India). Gel electrophoresis was done by a full set 
up of gel apparatus (Tarsons, India).
Preparation of the methanol fraction of TA (MFTA) bark
Bark of TA was collected from Raja Narendra Lal Khan Women’s 
College campus of Midnapore, Paschim Medinipur district of West 
Bengal, India. The material was designated by the taxonomist of the 
botany department at our college. Voucher specimens were deposited 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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in the department of botany. Preparation of MFTA was done as earlier 
modified work in our laboratory [2].
Animal model and administration of MFTA
The study was performed on 35 healthy adult male albino rats of Wister 
strain (Supplied from Saha Enterprise, 386/2, Nilachal, Birati, Kolkata, 
West Bengal 700051, Regd. No.:1828/PO/BT/S/15/Committee for 
the Purpose of Control and Supervision of Experiments on Animals 
[CPCSEA]) having a body weight of 200±15 g. They were acclimatized 
to laboratory condition for 2 weeks before experimentation. Animals 
were housed five rats/cage in a temperature-controlled room (22±2°C) 
with 12–12 h dark–light cycles (8.00–20.00 h light, 20.00–8.00 h dark) 
at a humidity of 50±10%. They were provided with standard food and 
water ad libitum throughout the experimental period. Animal care 
was provided according to the guiding principle for the care and use 
of animals (Olfert et al. 1993)[13]. This experiment was approved 
by our Institutional Animal Ethics Committee (Regd. No.: 1905/PO/
Re/S/2016/CPCSEA), guidelines followed by CPCSEA.
A total of 35 rats were divided into three Groups (n=5). Group 1; five 
animals were normal animals without inducing kidney injury and fed 
a normal diet with ad libitum water. Group 2; 15 animals were divided 
into three subgroups (A–5, A–10, and A–15); each subgroup was with 
five rats, APAP at the concentration of 500 mg 5 mL de-ionized water/kg 
of body weight/day was injected with peritoneal route at zero “0” day, 
at 5th day, at 10th day for 14 days (A-15, at “0” day denotes 15 days 
treated; A-10, at 5th day for 10 days treated and A-5, at 10th day for 
5 days treated by APAP) to achieve uremia and feed normal diet with ad 
libitum water. Group 3; 15 animals were subjected same as Group 2 with 
coadministered MFTA (TA-15, at zero “0” day denotes 15 days treated; 
TA-10, at 5th day for 10 days treated and TA-5, at 10th days for 5 days 
treated by APAP), at the dose of 40 mg/kg body weight by orally and 
feed normal diet with ad libitum water for 14 days daily at 11.00 A.M. 
before giving the food. APAP-induced uremia was established in our 
earlier research [8].
Animal scarification to collect plasma, organs, and urine
All rats were sacrificed on the 15th day. Blood was collected from the aorta 
and was centrifuged with heparin anticoagulant to collect the plasma. 
Plasma and kidneys were stored in −20°C for different biochemical 
analysis. Urine samples were collected directly from the bladder using 
a needle through the syringe. Collected sample was stored at −20°C. 
Urine samples were centrifuged using a micro centrifuge operating 
10,000 rpm for 10 min, supernatants were separated [14]. A small part 
of the kidney was fixed in Bouin’s fixative for histology.
Biochemical analysis by semi autoanalyzer, UV-VIS 
Spectrophotometer, and ELISA Plate Reader
Biochemical estimation of urea and creatinine level of plasma 
and urine were measured by commercially available standard kit 
with standard protocol for photometric determination by semi 
autoanalyzer [6,8]. SOD, catalase, MDA level of kidney tissue measured 
in UV-VIS Spectrophotometer by standard protocol [9,15,16]. IL-
18 [17,18], KIM-1 [18,19], and cystatin-C [20] were measured by 
commercially available standard kit with standard protocol for kit 
literature by an ELISA plate reader.
Polyacrylamide gel electrophoresis (PAGE)
Denaturing sodium dodecyl sulfate (SDS)-PAGE was made after over 
14 day’s period of either APAP administration or coadministration of 
MFTA in rats with normal feeding rats. Urine sample was centrifuged 
at 10,000 rpm for 10 min, and the supernatant was discarded. Pellet 
was mixed with an equal volume of ×2 electrophoresis sample buffer 
(0.125 m Tris-Hydrochloride, 4% SDS, 20% v/v glycerol, 0.2 M 
Dithiothreitol, and 0.02% bromophenol blue, pH 6.8), 5 µg protease 
cocktail and heated at 95°C for 5 min, was analyzed by SDS-PAGE 
according to the method of Laemmli using 15% acrylamide resolving 
gels and 10% stacking gel. Electrophoresis was performed on Tarson 
electrophoresis apparatus. After washing in water for 5 min, the 
gels were stained with Coomassie Brilliant Blue R250 (0.1% in 25% 
methanol, and 10% acetic acid). The distaining step was done with 
Coomassie Brilliant Blue by incubation in 30% acetic acid distinguished 
with blue stain for protein bands [21,22].
Histological examination
Kidney fixed in Bouin’s fixative for 24 h. Then kidney tissues were 
dehydrated with an elevated degree of ethanol and embedded in paraffin 
for preparing paraffin blocks. Sections from kidney tissue (4–5 mm) 
were stained with hematoxylin-eosin. The sections were examined and 
photographed by a Magnus MLX PLUS microscope (Nagano, Japan) [23].
Statistical Analysis
Data were analyzed using the origin software package (version 9.1). 
Analysis of variance (ANOVA) was followed by a multiple two-tail “t”-
test at the significance level (p<0.05) and expressed as SEM (n=5) [24].
RESULTS
Changes of old kidney disease biomarkers versus new kidney 
disease biomarkers of progression of kidney disease by APAP 
administration
APAP administration for 5 days in Group 2 (A-5) rats rises plasma urea 
38.39% and plasma creatinine 51.61% significantly (p<0.05) than 
untreated Group 1 rat, while IL-18, KIM-1 and cystatin-C level in urine 
raised in 75.41%, 93.50%, and 307.69%, respectively, then Group 1. 
All biomarkers in plasma and urine significantly increased (p<0.05) in 
Group 2 (A-5) than Group 1 (Table 1, Fig. 1 G-2a and G-2b).
APAP administration for 10 days in Group 2 (A-10) elevates plasma 
urea 112.11% and plasma creatinine 96.77% significantly (p<0.05) 
than untreated Group 1 rats, while IL-18, KIM-1, and cystatin-C level of 
Table 1: Changes of new biomarkers either APAP administration or co-administration of MFTA with APAP on plasma, urine, and kidney 
tissue. Data are expressed as SEM (n=5). ANOVA followed by multiple two-tail t-test and data with different superscripts letters (a, b, c, d, 
e, f, and g) revealed significant difference from each other (P<0.05). Group 1, normal rats without inducing kidney injury. Group 2, APAP 
administration rats groups (A-5, A-10, and A-15, respectively, APAP administration for 5 days, 10 days, and 15 days), Group 3: APAP with 
MFTA coadministration rats (TA-5, TA-10, and TA-15, respectively, APAP with MFTA coadministration for 5 days, 10 days, and 15 days)
Parameters Groups
Group 1 Group 2 Group 3
A-5 A-10 A-15 TA-5 TA-10 TA-15
Plasma urea (mg/dl) 25.42±0.18a 35.18±0.17b 53.92±0.39c 76.26±0.20d 31.46±0.46e 34.56±0.27f 35.44±0.35g
Urine urea (mg/dl) 88.30±0.26a 39.68±0.52b 38.04±0.30c 30.36±0.39d 40.96±0.27e 47.72±0.38f 56.32±0.82g
Plasma creatinine (mg/dl) 0.31±0.01a 0.47±0.01b 0.61±0.01c 0.76±0.01d 0.38±0.01e 0.41±0.01f 0.39±0.01g
Urine creatinine (mg/dl) 3.54±0.05a 1.34±0.05b 0.74±0.04c 0.51±0.03d 0.79±0.03e 1.03±0.03f 1.84±0.14g
Urine KIM-1 (pg/ml) 168.30±1.88a 295.22±1.73b  395.11±1.58c 495.04±1.98d 174.90±1.17e 194.20±3.40f 182.21±2.13g
Urine IL-18 (pg/ml) 14.94±0.17a 28.91±0.34b 39.07±0.16c 49.38±0.33d 18.26±0.17e 22.46±0.66f 27.22±0.96g
Urine cystatin C (µg/ml) 0.13±0.01a 1.13±0.01b 1.30±0.01c 1.44±0.01d 0.44±0.01e 0.34±0.01f 0.33±0.01g
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urine elevated in 161.51%, 134.76%, and 423.07%, respectively, than 
Group 1. All biomarkers in plasma and urine significantly increased 
(P<0.05) in Group 2 (A-10) than Group 1 (Table 1, Fig. 1 G-2a and G-2b).
APAP administration for 15 days in group 2 (A-15) increases plasma 
urea 200.00% and plasma creatinine 145.16% significantly (p<0.05) 
than untreated Group 1 rats, while IL-18, KIM-1, and cystatin-C level of 
urine increased in 230.52%, 194.14%, and 507.69%, respectively, then 
Group 1. All biomarkers in plasma and urine significantly increased 
(p< 0.05) in Group 2 (A-15) than Group 1 (Table 1, Figs. 1 G-2a and G-2b).
Effect of APAP administration for 5 days, 10 days, and 15 days created 
a vast difference between plasma old biomarkers and urinary proteo-
immuno new biomarkers. KIM-1 and cystatin-C are low molecular 
weight signaling proteins molecules. IL-18 is synthesized from tissue 
macrophages in epithelial cells of the proximal tubule.
Effect of MFTA on changes of old and new kidney disease 
biomarkers
Peritoneal administration of APAP with coadministration of MFTA orally 
for 5 days decreases plasma urea 23.76% and plasma creatinine 19.14% in 
Group 3 (TA-5) then Group 2 (A-5) rats, while IL-18, KIM-1, and cystatin-C 
level in urine decreased in 22.22%, 3.9%, and 16.98%, respectively, in 
TA-5 then A-5. All biomarkers in plasma and urine significantly decreased 
(p<0.05) in TA-5 than A-5 (Table 1, Figs. 1 G-3a and G-3b).
Peritoneal administration of APAP with coadministration of MFTA 
orally for 10 days in Group 3 (TA-10) reduces plasma urea 35.95% 
and plasma creatinine 32.78% then Group 2 (A-10) rats, while IL-18, 
KIM-1, and cystatin-C level in urine reduced in 50.33%, 15.38%, and 
50.00%, respectively, in TA-10 than A-10. All biomarkers in plasma and 
urine significantly reduced (p<0.05) in TA-10 than A-10 (Table 1, Figs. 1 
G-3a and G-3b).
Peritoneal administration of APAP with coadministration of MFTA 
orally for 15 days in Group 3 (TA-15) declines plasma urea 39.41% and 
plasma creatinine 48.68% then Group 2 (A-15) rats, while IL-18, KIM-1, 
and cystatin-C level in urine declined by 82.19%, 8.26%, and 58.22%, 
respectively, in TA-15 when compared to A-15. All biomarkers in plasma 
and urine significantly decreased (p<0.05) in TA-15 then A-15 (Table 1, 
Figs. 1 G-3a and G-3b).
Effect of MFTA on SOD, Catalase, and MDA (oxidative biomarkers)
Effect of APAP in co administration with MFTA on kidney tissue levels 
of SOD, catalase and MDA were shown in Table 2. Quantification level 
of SOD and catalase significantly low (P<0.05) in kidney tissue of A-5, 
A-10, and A-15 rats was compared to other two groups, but MDA level is 
significantly high (P<0.05) in compare to Group 1, TA-5, TA-10, and TA-
15. MFTA coadministration with APAP causes improvement of oxidative 
stress in kidney tissues.
Correlation between old biomarkers and new biomarkers
Correlation analysis was also represented graphically by a scatter 
diagram. Urine IL-18 correlates with plasma urea and urine KIM-1 
correlates with plasma creatinine. Urine IL-18 and urine KIM-1 values 
were taken on vertical axis versus plasma urea and plasma creatinine 
values on horizontal axis (Figs. 2 and 3). Group 1 represented a 
medium uphill (positive, r=0.434) relationship between urine IL-18 
and plasma urea (Fig. 3 G-1a) and a weak downhill (negative, r=0.257) 
relationship between urine KIM-1 and plasma creatinine (Fig. 3 G-1b). 
Group 2 showed APAP administration for 5 days (Group A-5), 10 days 
(Group A-10), and 15 days (Group A-15) a downhill (negative, r=0.302, 
0.066, and 0.754, respectively) relationship between urine IL-18 and 
plasma urea (Figs. 2 A-5A, 2 A-10A, A-15A). KIM-1 and plasma creatinine 
represent a strong uphill (positive, r=0.772) relationship (Fig. 3 A-5B), 
a medium downhill (negative, r=0.541) relationship (Fig. 3; A-10B) 
and a weak downhill (negative, r=0.294) relationship (Fig. 3 A-15B) in 
Fig. 1: Line diagram represents the percentage against duration of study (days). Urine IL-18 and plasma urea shows of group 2 (G-2a) and 
group 3 (G-3a) and urine KIM-1, cystatin-c, plasma creatinine shows of group 2 (G-2b) and group 3 (G-3 b). Fig.1: Line diagram represents 
the percentage against duration of study (days). Urine IL-18 and plasma urea shows of group 2 (G-2a) and group 3 (G-3a) and urine KIM-1, 
cystatin-c, plasma creatinine shows of group 2 (G-2b) and group 3 (G-3b)
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Group 2. Group 3 reveals MFTA coadministration with APAP a downhill 
(negative, r=0.758, 0.488) association (Figs. 2 TA-5A, TA-15A) and a 
strong uphill (positive, r=0.742) association (Fig. 2; TA-10A) in between 
urine IL-18 and plasma urea. KIM-1 and plasma creatinine correlation 
reveals a weak downhill (negative, r=0.024) relationship (Fig. 3 TA-15B) 
and a weak uphill (positive, r=0.035) relationship (Fig. 3 TA-5B) but a 
strong uphill (positive, r=0.972) relationship (Fig. 3 TA-10B) in Group 3.
Denaturing SDS-PAGE analysis
SDS-PAGE showed different protein aggregated bands (Fig. 4) 
corresponding to the molecular weight marker (MWM). MWM 
represented eight separate protein bands showing 75 Kilodalton (kDa) 
to 11 kDa in descending orders. C1 and C2 lane represented the urinary 
protein bands at 63, 20, and 11 kDa of Group 1 rats and there was no 
other band at 48, 38, 25, and 17 kDa. Urinary protein bands in Group 2 
observed new bands at 35 kDa in A1 and A2 lane when compared to C1 
and C2. It was also observed that band intensity at 11 kDa in A1 and A2 
lane was less than C1 and C2. The MFTA coadministration represented 
the urinary protein bands in Group 3 − 63, 20, and 11 kDa and less 
intensity bands in 11 kDa of TA1 and TA2. It also has shown no band in 
35 kDa that indicates improvement toward the normal condition.
Histological examination
The histological architecture of kidney indicated (Fig. 5) necrosis and 
atrophy in proximal tubule (black arrow in Fig. 5b) and glomerulus 
(black circle in Fig. 5b) in sub-group of Group 2 (APAP treated) compares 
Fig. 2: Scatter diagram represents the correlation in between Urine interleukin-18 (IL-18) and Plasma urea, G-1 A: normal rats group. A-5 
A: A-5 group rats (acetaminophen administration for 5 days), A-10 A: A-10 group rats (acetaminophen administration for 10 days), A-15 
A: A-15 group rats (acetaminophen administration for 15 days). TA-5 A: TA-5 group rats (methanol fraction of Terminalia arjuna [MFTA] 
co-administration with acetaminophen administration for 5 days), TA-10 A: TA-10 group rats (MFTA co-administration with acetaminophen 
administration for 10 days), TA-15 A: TA-15 group rats (MFTA co-administration with acetaminophen administration for 15 days)
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to Group 1. Group 1 shows a normal proximal tubule (black arrow in 
Fig. 5a) and glomerulus (black circle in Fig 5a). Peritubular congestion 
and epithelial desquamation (black star in Fig. 5b) increased in APAP 
treated group in compared to MFTA coadministration group (Group 3) 
and improved or prevented injuries by regenerating normal glomerulus 
with light Bowmans degeneration and renal tubules (black circle in 
Fig. 5c, black arrow in Fig. 5c).
Old biomarkers versus new biomarkers on duration dependent 
study
Our study shown by line diagrams, increased percentage of old 
biomarkers (urea and creatinine) is less than the increased level of 
new biomarkers depends on the duration of the study. IL-18 and 
plasma urea level of Group 2 when compared with Group 1, the result 
proves the enriched level of IL-18 increased by 93.50%, 161.51%, and 
230.52%, respectively, in 5th, 10th, and 15th days but while plasma urea 
level increased in only 38.39%, 112.11%, and 200.00%, respectively, in 
5th, 10th, and 15th days for low sensitivity and protectivity (Fig. 1 G-2a). 
Furthermore, KIM-1, cystatin-C, and plasma creatinine when compared 
with Group 1, there the result shows KIM-1 level in 75.41%, 134.76%, 
and 194.14% and cystatin-C level in 307.69%, 423.07%, and 507.69% 
increased, respectively, in 5th, 10th, and 15th days but plasma creatinine 
shows 51.61%, 96.77%, and 145.16%, respectively, in 5th, 10th, 
and 15th days for poor sensitivity and protectivity in kidney injury 
Fig. 3: Scatter diagram represents the correlation in between Urine KIM-1 and Plasma creatinine, G-1 B: normal rats group. A-5 B: A-5 
group rats (acetaminophen administration for 5 days), A-10 B: A-10 group rats (acetaminophen administration for 10 days), A-15 B: A-15 
group rats (acetaminophen administration for 15 days). TA-5 B: TA-5 group rats (methanol fraction of Terminalia arjuna [MFTA] co-
administration with acetaminophen administration for 5 days), TA-10 B: TA-10 group rats (MFTA co-administration with acetaminophen 
administration for 10 days), TA-15 B: TA-15 group rats (MFTA co-administration with acetaminophen administration for 15 days)
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interstitium [25]. The study demonstrated that APAP administration 
in rats raises plasma urea 38.39% for 5 days, 112.11% for 10 days, 
and 200.00% for 15 days while urinary IL-18 raise 75.41% for 5 days, 
161.51% for 10 days, and 230.52% for 15 days. Urinary biomarker is 
IL-18 (24 kDa), a proinflammatory and immunomodulatory cytokine 
in distal convoluted tubule and collecting tubule in kidney [26]. A mild 
injury or stress in distal and collecting tubule, elevation of IL-18 occurs 
invasive amount [27]. Plasma creatinine, end product of muscle protein 
breakdown, showed high in the late destructive stage of kidney [28]. 
We elaborate APAP administration in rats elevates plasma creatinine 
51.61% for 5 days, 96.77% for 10 days, and 145.16% for 15 days even 
as urinary KIM-1 lifts up 75.41% for 5 days, 134.76% for 10 days, 
and 194.14% for 15 days. KIM-1, which found in proximal tubular 
epithelium transmembrane glycoprotein (90 kDa) absent in normal 
kidney tissue or urine. KIM-1 increased and excreted in urine a huge 
amount by mild tubular stress [29]. A low molecular weight protein 
(13 kDa) cystatin-C is prepared in all organs in our body while oxidative 
damage based necrosis of cells and tissues. It is completely assured by 
normal nephrons. It is contained in urine when any part of nephrons 
gets damaged [30]. First 5 days APAP administration increases urinary 
cystatin-C level 307.69%, thereafter, 423.07% for 10 days, 507.69% 
for 15 days. However, it is distinctly clear urinary IL-18, KIM-1, 
and cystatin-C showing a higher level in duration dependent APAP 
administration than plasma urea and plasma creatinine. In our study, 
coadministrated MFTA with APAP to another groups of rats which was 
effective in reducing old kidney biomarkers plasma urea, creatinine, 
and new kidney biomarkers urinary IL-18, KIM-1, and cystatin-C. 
The authors speculate that antioxidant enzymes, SOD, and catalase 
Fig. 4: Electrophoresis of urine samples from normal (C1 and 
C2), administration of acetaminophen (APAP) administration 
(A1 and A2), APAP with co-administration of methanol fraction 
of Terminalia arjuna (MFTA) (TA1 and TA2) performed under 
SDS-PAGE were run along with standard molecular weight 
markers (MWM). Patterns represent three different urinary 
fraction of rat’s urine. (lane C1 and C2) Group 1 (normal rat urine 
sample), (lane A1 and A2) A-15 group (APAP treated for 15 days 
urine sample), (lane TA1 and TA2) TA-15 group (APAP treated for 
15 days urine sample with co-administration of MFTA)
(Fig. 1 G-2b). The percentage levels in Group 3 compared to Group 2 of 
IL-18, and plasma urea was decreased at an equal level at the presence 
of MFTA, 36.83%, 42.51%, and 44.87% and 10.57%, 35.90%, and 
53.52%, respectively, in 5th, 10th, and 15th days (Fig. 1 G-3a). Identical 
same result was also found with KIM-1(40.75%, 50.84%, and 63.19%, 
respectively, in 5th, 10th, and 15th days), cystatin-C (16.98%, 50.00%, and 
58.22%, respectively, in 5th, 10th, and 15th days), and plasma creatinine 
(19.14%, 32.78%, and 48.68%, respectively, in 5th, 10th, and 15th days) 
(Fig. 1 G-3b).
DISCUSSION
Our earlier investigation, acetaminophen-induced nephrotoxicity [8], 
MFTA having three major polyphenols details published earlier 
by corresponding author [2] showed nephroprotective activity on 
old biomarkers those were urea and creatinine [6] and also MFTA 
established as a powerful antioxidant evidenced on SOD, catalase, and 
MDA on kidney tissue [5]. Plasma urea is synthesized in liver, and plasma 
creatinine is a breakdown product of muscle protein, both were expected 
in late stages of kidney disease [29]. Plasma urea is screened high at 
late stages of kidney diseases. Used of plasma urea old biomarker at 
late stage patients suffer irreversible destruction and damage of kidney 
Table 2: Changes of old biomarkers either APAP administration or coadministration of MFTA with APAP on plasma, urine, and kidney 
tissue. Data are expressed as SEM (n=5). ANOVA followed by multiple two-tail t-test and data with different superscripts letters (a, b, c, d, 
e, f, and g) revealed significant difference from each other (P<0.05). Group 1, normal rats without inducing kidney injury. Group 2, APAP 
administration rats groups (A-5, A-10, and A-15, respectively, APAP administration for 5 days, 10 days, and 15 days), and Group 3: APAP 
with MFTA coadministration rats (TA-5, TA-10, and TA-15, respectively, APAP with MFTA coadministration for 5 days, 10 days, and 15 days).
Parameters Groups
Group 1 Group 2 Group 3
A-5 A-10 A-15 TA-5 TA-10 TA-15
MDA (nmol/mg of tissue) 40.05±0.15a 79.07±0.31b 94.73±0.30c 98.92±0.25d 56.05±0.30e 59.47±0.25f 61.13±0.2g
SOD (mmolof H2O2 consumption/mg of tissue/min) 0.87±0.01a 0.11±0.01b 0.16±0.01c 0.25±0.01d 0.42±0.01e 0.50±0.0f 0.56±0.01g
Catalase (mmol of H2O2 consumption/mg of tissue/min) 0.57±0.01a 0.13±0.01b 0.19±0.01c 0.21±0.01d 0.37±0.01e 0.40±0.01f 0.41±0.01g
MDA: Malondialdehyde
Fig. 5: Histological changes in kidney of rats. (a) Group 1 (normal 
rats, without inducing kidney injury rat kidney), (b) Group 2 
(acetaminophen treated kidney of A-15 sub-group), (c) Group 3 
(acetaminophen treated kidney with co-administration of 
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in kidney tissues significantly enhanced and significantly diminished 
MDA by MFTA feeding orally [6]. It is difficult to conclude with the exact 
mechanism by which MFTA controls the kidney biomarkers. It should 
be hypothesized that three major compounds (earlier published, [2]) 
have a significant main effect on renal tubules.
Evidence from correlation study in between plasma urea and urine 
IL-18 in untreated rats, APAP administration for 5 days and 10 days, 
there was no significant relation of urea and IL-18 while significantly 
related to 15 days APAP administration. Plasma creatinine was 
not significantly correlated with urinary KIM-1 where there were 
strongly significant correlated with APAP administration for 5 days. 
MFTA causes negative correlation with plasma creatinine and 
urinary KIM-1.
Urinary IL-18, KIM-1, and cystatin-C are low molecular protein 
measured by ELISA kit method which was strong evidenced with the 
presence of extra band around 25–30 kDa of APAP administration by 
SDS-PAGE. Histological observations showed according to Abhirama 
et al., tubular degeneration, desquamation, necrosis, intertubular 
hemorrhage, and hyaline in tubules with congestion and swelling in 
glomerulus evaluated due to nephrotoxicity in animals [31]. However, 
coadministration of MFTA caused marked histological protection on 
tissue injuries including tubular necrosis, capillary congestion, and 
epithelial desquamation against APAP administration in Group 3. 
Cirevalli et al. suggested that CKD patient with low-income also against 
the provision of various drugs to reduce the financial burden on 
pharmaceutical costs not only for the patient but also to caregivers to 
their family [32].
CONCLUSION
It can be possible to conclude that the use of these urinary low 
molecular weight proteins biomarkers could be used to monitor at risk 
in kidney disease patients. These biomarkers will allow to diagnose 
kidney disease at a much earlier stage. MFTA possess anti-uremic and 
urinary biomarkers suppressive capacity. The kidney protective effect 
in this study provides a mechanistic evidence for why tribal people 
in our Jangalmahal area of Paschim Medinipur and Jhargram, state of 
West Bengal, India found it useful for treating kidney ailments as well 
as being used to cure other health disorders.
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